Shares of Sandoz Group AG (OTCMKTS:SDZNY - Get Free Report) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $50.76 and last traded at $50.76, with a volume of 31253 shares traded. The stock had previously closed at $48.90.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the company. Royal Bank of Canada upgraded Sandoz Group from a "hold" rating to a "moderate buy" rating in a research note on Friday, May 2nd. UBS Group lowered Sandoz Group from a "strong-buy" rating to a "hold" rating in a research note on Monday, February 3rd.
View Our Latest Stock Report on Sandoz Group
Sandoz Group Stock Down 0.4%
The company has a fifty day moving average of $43.58 and a 200-day moving average of $44.00.
Sandoz Group Company Profile
(
Get Free Report)
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.
Featured Stories
Before you consider Sandoz Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sandoz Group wasn't on the list.
While Sandoz Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
